TAl/Tau Aggregation inhibiting Peptide
Price range: $120.00 through $200.00
The function of Tau protein aggregation inhibitory peptides is to inhibit the aggregation of Tau protein. This may play a crucial role in the treatment of diseases related to Tau protein, such as Alzheimer’s disease. These peptides can pass through the blood-brain barrier and effectively inhibit the aggregation of Tau protein in both in vitro and in vivo models, and improve the associated neurodegenerative and behavioral defects.
Description
Inhibiting Tau protein aggregation: The core mechanism is to prevent the abnormal aggregation of Tau protein, which is one of the key factors leading to damage and death of nerve cells.
Improving neurodegenerative diseases: By inhibiting the aggregation of Tau protein, it helps to delay or improve the progression of neurodegenerative diseases, such as Alzheimer’s disease, etc.
Improving behavioral phenotypes: In disease models, these peptides not only can inhibit pathological changes but also can improve related behavioral problems.
Crossing the blood-brain barrier: Some of these peptides (such as RI-AG03) have oral activity and can cross the blood-brain barrier, which makes them potentially effective therapeutic drugs.
Additional information
| Weight | 500 g |
|---|---|
| Dimensions | 20 × 10 × 8 cm |
| FORMAT | 10Bottlex5mg, 10Bottlex10mg |





